Ardelyx Inc. Updates
Abstract Accepted for Poster Presentation at Digestive Disease Week 2026
On 23 April 2026, Ardelyx Inc. (NASDAQ: ARDX) announced that an abstract describing its research on irritable bowel syndrome with constipation (IBS‑C) treatment patterns has been accepted for poster presentation at the upcoming Digestive Disease Week 2026 conference. The study focuses on real‑world treatment patterns for IBS‑C, a condition that aligns with Ardelyx’s portfolio of therapies aimed at correcting mineral metabolism imbalances and metabolic disorders through modulation of gastrointestinal epithelial transporters, channels, and receptors. The abstract will be presented in the poster session, offering an opportunity for the company to share its findings with a global audience of clinicians and researchers.
Stock Performance and Analyst Commentary
During trading on 23 April 2026, Ardelyx shares fell below the 200‑day moving average, registering a low of $5.94 against a moving average of $6.11. The closing price that day was $6.02, with a trading volume of 2,962,058 shares.
Brokerage coverage remains mixed:
| Brokerage | Rating | Target Price |
|---|---|---|
| Citigroup | Buy | $14.00 |
| Weiss Ratings | Sell (d-) | — |
| TD Cowen | Buy | — |
| Williams Trading | — | $17.00 |
| Raymond James Financial | Strong Buy | $19.00 |
An aggregate consensus rating of “Moderate Buy” has been reported, with a consensus target price of $15.70. Key financial metrics at the time of the latest update include:
- Market capitalization: $1.48 billion
- Current ratio: 4.31
- Quick ratio: 4.11
- Debt‑to‑equity ratio: 1.21
- P/E ratio: –24.08
The company’s most recent quarterly earnings, released 19 February 2026, reported earnings per share of –$0.01.
Leadership Movement from Ardelyx to Jade Biosciences
On 22 April 2026, Jade Biosciences Inc. (NASDAQ: JBIO) announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer. Dr. Conner’s experience includes previous roles as CMO at Ardelyx Inc., Third Harmonic Bio, and Locanabio. His background in clinical development, translational medicine, and regulatory strategy will support Jade’s pipeline of therapies for autoimmune diseases. While this movement does not directly alter Ardelyx’s current operations, it highlights the mobility of executive talent within the biotechnology sector.
All information is derived from the provided financial news and company fundamentals.
